BioFluidica, a US-based privately held biotechnology company, announced on Friday that it planning to commercialise the LiquidScan Automated Liquid Biopsy System, a high throughput rare biomarker (circulating tumour cells, exosomes, and cell-free DNA) enrichment solution.
The company has designed and developed an automation-ready liquid biopsy instrument compatible with Hamilton Robotics Microlab STAR series liquid handlers. The commercial version of the LiquidScan system is produced under present Good Manufacturing Practices and includes complete documentation to facilitate clinical application development and clinical trials under EUA and FDA guidelines.
BioFluidica is offering a limited number of systems to certain Core facilities in North America through Early Technology Access Program from fourth quarter of 2021.
Rocket Pharmaceuticals closes USD180m Rare Pediatric Disease voucher sale
Airiver Medical treats first chronic rhinosinusitis patient in Drug Coated Balloon clinical study
Precigen and the RRPF recognise International RRP Awareness Day
Guardant Health expands FDA-approved companion diagnostic use for HERNEXEOS
FDA grants priority review for Genentech's Tecentriq in stage III dMMR/MSI-H colon cancer
Formosa Pharmaceuticals signs Vietnam licensing deal with Samil Pharmaceuticals
Harbour BioMed IND for HBM7004 accepted by China's NMPA
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
FDA grants rare paediatric disease designation to RedHill's opaganib
GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio
Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development
Alvotech reports FDA review acceptance for Entyvio biosimilar candidate AVT16
Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline